COVID-19 Updates
From the Journals
Infliximab weakens COVID-19 antibody response for IBD patients
Anti–COVID-19 antibodies were impaired in patients with IBD treated with infliximab, compared with those on vedolizumab.
From the Journals
COVID-19 may alter gut microbiota
Changes in gut microorganisms may contribute to severe disease and long-term symptoms after the virus clears.
From the Journals
COVID-19 may damage blood vessels in the brain
A postmortem study reveals signs of vascular inflammation in the brains of deceased patients.
From the Journals
Liver disease associated with worse COVID-19 outcomes
More than 90% of patients can develop increased levels of ALT and AST, and these elevations appear to mirror disease severity.
From the Journals
COVID-19 ranks as a leading cause of death in United States
“The current exponential increase in COVID-19 is reaching a calamitous scale in the U.S.”
From the Journals
COVID-19 vaccines: Safe for immunocompromised patients?
Data are limited thus far, and the safety and efficacy of the COVID-19 vaccines in immunocompromised patients remain unknown.
Conference Coverage
Liver injury linked to COVID-19–related coagulopathy
Cells that line the liver's blood vessels produce high levels of factor VIII, a coagulation factor, when they are exposed to interleukin-6, an...
Feature
AMA takes on vaccine misinformation, physician vaccines, racism
The AMA House of Delegates recently issued multiple new policies on controversial topics that many clinicians face on a regular basis.
From the Journals
COVID exposure risk outside of work increasing for clinicians
Two-thirds (66%) of the higher-risk exposures occurred during direct patient care and 34% were related to nonpatient care interactions.
Feature
VA joins Pentagon in recruiting volunteers for COVID vaccine trials
“With VA, their population, all elderly and infirm with underlying conditions, they could really be suffering if we don’t get a vaccine.”